NOVA SOUTHEASTERN UNIVERSITY

Global Clinical Trial Launches to Test Sipavibart as Potential Long COVID Treatment

a month ago

• Nova Southeastern University researchers have begun a clinical trial testing AstraZeneca's monoclonal antibody sipavibart as a potential treatment for Long COVID, funded by the Schmidt Initiative for Long COVID. • The double-blind, randomized controlled trial will enroll 100 patients to evaluate whether sipavibart, already approved for COVID-19 prevention in Japan and the EU, can improve cognitive dysfunction, autonomic nervous system effects, and exercise tolerance. • This trial is one of three Long COVID treatment studies launching in 2025, alongside another global study testing anti-inflammatory drugs upadacitinib and pirfenidone across seven locations on four continents.

Gene Therapy Shows Promise in Targeting Alzheimer's Disease

5 months ago

• Gene therapy is emerging as a novel approach for Alzheimer's, bypassing the amyloid and tau protein focus by targeting the underlying genetics. • Lexeo Therapeutics' Phase 1/2 trial delivers the APOE2 gene to patients with the APOE4 allele, showing early positive results with reduced tau protein levels. • A separate Phase 1 trial at UCSD uses gene therapy to deliver BDNF, aiming to rebuild brain circuits and prevent neuronal death in Alzheimer's patients. • Researchers are optimistic about gene therapy's potential to address multiple pathologies and offer preventative treatments for Alzheimer's disease.

ZEO ScientifiX Launches Regenerative Medicine Educational Series for Physicians

7 months ago

• ZEO ScientifiX has initiated a monthly educational series for healthcare providers, focusing on regenerative medicine advancements and clinical applications. • The series emphasizes the therapeutic potential of extracellular vesicles and autologous biologics, offering practical business solutions for medical practice integration. • ZEO recently completed Phase 1 clinical trials for Zofin™ and plans to launch Phase 2 trials for various disease indications, seeking FDA approval. • The regenerative medicine market is projected to reach $175 billion by 2032, with an annual growth rate of 22.8%, according to Precedence Research.